DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery.
Nat Rev Cancer, 2005, 5:876–885.
Gaddum JH. Theories of drug antagonism. Pharmacol Rev,
1957, 9:211–218.
Gay NJ, Gangloff M. Structure and function of toll receptors and
their ligands. Annu Rev Biochem, 2007, 76:141–165.
Ghavami S, Hashemi M, Ande SR, et al. Apoptosis and cancer:
Mutations within caspase genes. J Med Genet, 2009,
46:497–510.
Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways
in cancer therapy. CA Cancer J Clin, 2005, 55:178–194.
Ghosh S, Hayden MS. New regulators of NFκB in inflammation.
Nat Rev Immunol, 2008, 8:837–848.
Gilman AG. G proteins: Transducers of receptor-generated signals.
Annu Rev Biochem, 1987, 56:615–649.
Gough DJ, Levy DE, Johnstone RW, Clarke CJ. IFN-γ signaling-does
it mean JAK-STAT? Cytokine Growth Factor Rev,
2008, 19:383–394.
Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms.
Annu Rev Pharmacol Toxicol, 2001, 41:145–174.
Hayden MS, Ghosh S. Shared principles in NFκB signaling.
Cell, 2008, 132:344–362.
Hubbard SR, Till JH. Protein tyrosine kinase structure and function.
Annu Rev Biochem, 2000, 69:373–398.
Hudmon A, Schulman H. Structure-function of the multifunctional
Ca 2+ /calmodulin-dependent protein kinase II. Biochem J,
2002, 364:593–611.
Jain KK. Role of pharmacoproteomics in the development of
personalized medicine. Pharmacogenomics, 2004, 5:331–336.
Jegla TJ, Zmasek CM, Batalov S, Nayak SK. Evolution of the
human ion channel set. Comb Chem High Throughput Screen,
2009, 12:2–23.
Kalaany NY, Mangelsdorf DJ. LXRs and FXR: The yin and yang
of cholesterol and fat metabolism. Annu Rev Physiol, 2006,
68:159–191.
Kataoka T. Chemical biology of inflammatory cytokine signaling.
J Antibiot (Tokyo), 2009.
Kenakin T. Efficacy as a vector: The relative prevalence and
paucity of inverse agonism. Mol Pharmacol, 2004, 65:2–11.
Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin
dose with clinical and pharmacogenetic data. N Engl J
Med, 2009, 360:753–764.
Limbird LE. Cell Surface Receptors: A Short Course on Theory
and Methods. Springer-Verlag, 2005.
Manning AM, Davis RJ. Targeting JNK for therapeutic benefit:
From junk to gold? Nat Rev Drug Discov, 2003, 2:554–565.
May LT, Leach K, Sexton PM, Christopoulos A. Allosteric modulation
of G protein-coupled receptors. Annu Rev Pharmacol
Toxicol, 2007, 47:1–51.
Mayr B, Montminy M. Transcriptional regulation by the
phosphorylation-dependent factor creb. Nat Rev Mol Cell Biol,
2001, 2:599–609.
McEwan IJ. Nuclear receptors: One big family. Methods Mol
Biol, 2009, 505:3–18.
Mehats C, Andersen CB, Filopanti M, et al. Cyclic nucleotide
phosphodiesterases and their role in endocrine cell signaling.
Trends Endocrinol Metab, 2002, 13:29–35.
Milligan G. Constitutive activity and inverse agonists of G
protein-coupled receptors: A current perspective. Mol
Pharmacol, 2003, 64:1271–1276.
Moore CA, Milano SK, Benovic JL. Regulation of receptor trafficking
by GRKs and arrestins. Annu Rev Physiol, 2007,
69:451–482.
Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of
rhodopsin: A G protein-coupled receptor. Science, 2000,
289:739–745.
Patterson RL, Boehning D, Snyder SH. Inositol 1,4,5-trisphosphate
receptors as signal integrators. Annu Rev Biochem, 2004,
73:437–465.
Potter LR, Yoder AR, Flora DR, et al. Natriuretic peptides: Their
structures, receptors, physiologic functions and therapeutic
applications. Handb Exp Pharmacol, 2009, 341–366.
Prakriya M. The molecular physiology of CRAC channels.
Immunol Rev, 2009, 231:88–98.
Privalsky ML. The role of corepressors in transcriptional regulation
by nuclear hormone receptors. Annu Rev Physiol, 2004,
66:315–360.
Purves D, Augustine GJ, Fitzpatrick D, et al. Channels and transporters.
In, Neuroscience. Sinauer, Sunderland, MA, 2008,
pp. 61–84.
Riggs BL, Hartmann LC. Selective estrogen-receptor modulators—mechanisms
of action and application to clinical practice.
N Engl J Med, 2003, 348:618–629.
Rogawski MA, Bazil CW. New molecular targets for antiepileptic
drugs: α 2
δ, SV2a, and K v
7/KCNQ Potassium Channels.
Curr Neurol Neurosci Rep, 2008, 8:345–352.
Rong Y, Distelhorst CW. Bcl-2 protein family members: Versatile
regulators of calcium signaling in cell survival and apoptosis.
Annu Rev Physiol, 2008, 70:73–91.
Roscioni SS, Elzinga CR, Schmidt M. Epac: Effectors and biological
functions. Naunyn Schmiedebergs Arch Pharmacol,
2008, 377:345–357.
Ross EM, Wilkie TM. GTPase-activating proteins for heterotrimeric
G proteins: Regulators of G protein signaling
(RGS) and RGS-like proteins. Annu Rev Biochem, 2000,
69:795–827.
Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP
phosphodiesterases and regulation of smooth muscle function.
Circ Res, 2003, 93:280–291.
Sands WA, Palmer TM. Regulating gene transcription in response
to cyclic AMP elevation. Cell Signal, 2008, 20:460–466.
Schild HO. Drug antagonism and pA 2
. Pharmacol Rev, 1957,
9:242–246.
Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NFκBregulatory
pathways. Annu Rev Biochem, 2009, 78: 769–796.
Smit MJ, Vischer HF, Bakker RA, et al. Pharmacogenomic and
structural analysis of constitutive G protein-coupled receptor
activity. Annu Rev Pharmacol Toxicol, 2007, 47:53–87.
Strasser A, O’Connor L, Dixit VM. Apoptosis signaling. Annu
Rev Biochem, 2000, 69:217–245.
Taylor SS, Kim C, Cheng CY, et al. Signaling through cAMP
and cAMP-dependent protein kinase: Diverse strategies for
drug design. Biochim Biophys Acta, 2008, 1784:16–26.
Tontonoz P, Spiegelman BM. Fat and beyond: The diverse
biology of PPARγ. Annu Rev Biochem, 2008, 77: 289–312.
Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular
pathophysiology and therapeutics. Pharmacol Ther, 2009,
122:216–238.
Venkatachalam K, Montell C. TRP Channels. Annu Rev
Biochem, 2007, 76:387–417.
71
CHAPTER 3
PHARMACODYNAMICS: MOLECULAR MECHANISMS OF DRUG ACTION